Lipodystrophy in patients with acromegaly receiving pegvisomant

被引:41
作者
Bonert, Vivien S. [1 ]
Kennedy, Laurence [2 ]
Petersenn, Stephan [3 ]
Barkan, Ariel [4 ,5 ]
Carmichael, John [1 ]
Melmed, Shlomo [1 ]
机构
[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA
[2] Univ Florida, Dept Med, Gainesville, FL 32610 USA
[3] Univ Duisburg Essen, Med Ctr, Div Endocrinol, D-47048 Duisburg, Germany
[4] Univ Michigan, Med Ctr, Dept Neurosurg, Ann Arbor, MI 48105 USA
[5] Univ Michigan, Med Ctr, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48105 USA
关键词
D O I
10.1210/jc.2008-0833
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Pegvisomant, a GH receptor antagonist, suppresses serum IGF-I levels into the normal range in more than 95% of patients with acromegaly. Documented side effects in the initial registration studies included headache, injection-site reactions, flu-like syndrome, and reversible elevation of hepatic enzymes. Objective: We report seven patients with acromegaly treated with pegvisomant who developed lipodystrophy at the site of injection (anterior abdominal wall, thigh, buttock, and upper arm). This side effect resulted in discontinuation of pegvisomant in four patients, with subsequent regression of lipohypertrophy. Subjects: Six female and one male patient with acromegaly, aged 24 -59 yr, are reported. All patients had undergone prior transsphenoidal surgery, and four received subsequent radiotherapy. Four patients had been treated with maximal doses of somatostatin analogs with partial suppression of IGF-I levels before initiation of pegvisomant therapy. Pegvisomant suppressed IGF-I levels into the normal range in five of seven subjects, before discontinuation of the drug. Two of seven patients received pegvisomant as first-line medical therapy, without prior somatostatin analog treatment, and one received combination therapy with a long-acting somatostatin analog and weekly pegvisomant injections. One patient experienced an erythematous superficial injection-site reaction that responded to application of steroid cream before the onset of lipohypertrophy. Conclusions: We report seven patients with acromegaly who developed lipohypertrophy at the pegvisomant injection site. Pegvisomant was discontinued due to dissatisfaction with lipohypertrophy by four patients. Lipohypertrophy regressed in all patients when the medication was discontinued. Lipohypertrophy recurred when two patients were rechallenged with pegvisomant. Patients receiving pegvisomant should undergo frequent examination of injection sites for lipohypertrophy.
引用
收藏
页码:3515 / 3518
页数:4
相关论文
共 20 条
[1]   Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly [J].
Atmaca, A ;
Erbas, T .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (06) :340-343
[2]   Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant [J].
Barkan, AL ;
Burman, P ;
Clemmons, DR ;
Drake, WM ;
Gagel, RF ;
Harris, PE ;
Trainer, PJ ;
van der Lely, AJ ;
Vance, ML .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5684-5691
[3]   Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis [J].
Biering, H ;
Saller, B ;
Bauditz, J ;
Pirlich, M ;
Rudolph, B ;
Johne, A ;
Buchfelder, M ;
Mann, K ;
Droste, M ;
Schreiber, T ;
Lochs, H ;
Strasburger, CJ .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (02) :213-220
[4]   EFFECT OF HUMAN GROWTH-HORMONE TREATMENT ON ADIPOSE-TISSUE IN CHILDREN [J].
BROOK, CGD .
ARCHIVES OF DISEASE IN CHILDHOOD, 1973, 48 (09) :725-728
[5]   Localized involutional lipoatrophy: A clinicopathologic study of 16 patients [J].
Dahl, PR ;
Zalla, MJ ;
Winkelmann, RK .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 35 (04) :523-528
[6]   Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant [J].
Drake, WM ;
Rowles, SV ;
Roberts, ME ;
Fode, FK ;
Besser, GM ;
Monson, JP ;
Trainer, PJ .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 149 (06) :521-527
[7]   Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant [J].
Feenstra, J ;
van Aken, MO ;
de Herder, WW ;
Feelders, RA ;
van der Lely, AJ .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (06) :805-806
[8]   Lipodystrophies [J].
Garg, A .
AMERICAN JOURNAL OF MEDICINE, 2000, 108 (02) :143-152
[9]   A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults [J].
Gotherstrom, G. ;
Bengtsson, B. -A. ;
Bosaeus, I. ;
Johannsson, G. ;
Svensson, J. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04) :1442-1445
[10]   Epidemiology of Acromegaly [J].
Holdaway I.M. ;
Rajasoorya C. .
Pituitary, 1999, 2 (1) :29-41